CELL CULTURE MARKET - 3D Cell Cultures: Next Generation & New Challenges
Kevin James and Robert G. Hunter of BCC Research say significant growth within the biopharmaceuticals industry is spurring unprecedented innovation in and demand for cell culture products for the purposes of drug discovery and safety testing. While 2D cell cultures have been in laboratory use since the 1950s, the market for 3D cultures has witnessed spectacular growth throughout the past decade.
SINGLE-USE MARKET - Rise of Single-Use Technologies & Systems in Biopharmaceuticals
Kevin James and Shalini S. Dewan of BCC Research believe eliminating the risk of contamination is the greatest challenge faced by manufacturers of biopharmaceuticals, and currently, this requires high-level monitoring of critical manufacturing processes. Single-use technology aids biopharmaceutical manufacturers in overcoming this challenge by reducing or eliminating the need for sterilization between batches, thereby improving operational efficiency.
COLORECTAL CANCER MARKET - Targeted & Immune System-Based Therapeutics Emerge as Prominent Treatment Modalities
Barbara Gilmore, Frost & Sullivan Analyst, reports that a vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer. High incidence of the disease, unmet clinical needs, and significant commercial potential are attracting drug developers to the market.
STEM CELL MARKET - Stem Cell Therapy to Redefine Regenerative Medicine
Jane C. Andrews, PhD, Frost & Sullivan Analyst, says faced with increasing challenges, such as costly treatments and treatments that are palliative rather than symptomatic, the global healthcare industry today is gradually transforming itself. With few existing therapies capable of curing or significantly changing the course of a disease, healthcare providers are starting to look toward regenerative medicine as a viable alternative.
ALBUMIN MARKET - Global Human Albumin Market: Extra Revenues to Come Through Non-Therapeutic Applications
Aish Vivekanandan, Frost & Sullivan Analyst, reports that human albumin is widely considered as a plasma replacement or expander for therapeutic purposes. However, for over a decade, the healthcare industry has been exploring the use of human albumin as a non-therapeutic substance/excipient for commercial settings.
EXECUTIVE INTERVIEW - Unither Pharmaceuticals: Premeasured Dosage Forms to Improve Medication Adherence
Eric Goupil, CEO Unither Pharmaceuticals, speaks frankly about medication adherence, Unither’s technology, and some of the challenges that they face today.
MICRONEEDLE TECHNOLOGY - The New Potential of Microneedles for Biologics & Small Molecules
Lisa A. Dick, PhD, describes how microneedle technology is being applied in two new transdermal systems using solid and hollow microneedles, which have the ability to deliver small molecules as well as biologics, opening up the potential for self-administration of a broad array of APIs
LOC-BASED DEVICES - Lab on Chip – How Far Are We Along the Road?
Divyaa Ravishankar, MS, indicates LOC-based devices are an integration of multiple disciplines and the miniaturization of the major laboratory procedures. Recently, these devices are branching into additional aspects of healthcare, such as drug delivery, stem cell, environmental monitoring, and synthetic biology.
ADVANCED DELIVERY DEVICES - Implantable Drug-Eluting Devices: A Novel Approach to Patient Care
Samuel D. Trohman, MBA, Joey L. Glassco, Elena Draganoiu, PhD, and Carey Boyum present developmental and commercial examples of non-biodegradable drug-eluting devices, along with the versatile properties of thermoplastic polyurethanes for the development of effective drug delivery systems.
ORODISPERSIBLE TABLETS - Advanced Drug Delivery for Repositioning Promethazine for Improved Application & Patient Outcomes
Srinivas Tipparaju, PhD, Anastasia Groshev, Danielle Dantuma, et al designed and characterized a formulation of ODTs at three different compression settings to determine the effective formulation for manufacturing rapid-release ODT promethazine tablets.
SOLUBILIZATION TECHNOLOGY - How to Choose the Right Solubilization Technology for Your API
Matt Wessel, PhD, Tom Reynolds, PhD, Sanjay Konagurthu, PhD, and Marshall Crew, PhD, present a brief overview of the various solubilization technologies, and a high-level strategy to aid in the selection of an appropriate formulation technology.
PRIMARY PACKAGING - Ophthalmic Squeeze Dispenser (OSD): Does One Size Fit All?
Degenhard Marx, PhD, and Matthias Birkhoff, discuss how the use of preservatives in eye drops is still controversial, but more and more evidence supports the use of unpreserved eye drops for treatment of chronic diseases.
EXECUTIVE INTERVIEW - Vetter: Helping Small Biotech Companies Execute a Successful Drug Development Process
Dr. Susanne Resatz, President of Vetter Development Services USA, Inc., discusses the many benefits to small biotech companies in utilizing a full-service CDMO, and what advanced services the Chicago-based facility offers its growing customer base.
EXECUTIVE INTERVIEW - ALTHEA: Giving Biopharmaceutical Companies the Power To Make
David Enloe, Althea’s President and CEO, discusses his company’s business strategy, why companies choose Althea, trends in the CMO industry, and how the company is growing since the acquisition of Ajinomoto.
SYRINGE SYSTEM - The Credence Companion Syringe System Delivers on Safety & Usability Using Human Factors Studies
John A. Merhige, MEM, and Lisa Caparra, RN, explain how development of the Companion product line has been driven by these two constituents, the innovation driven by the end-users’ needs and the avoidance of change driven by needs of the drug manufacturer.
FORMULATION DEVELOPMENT TECHNOLOGY - A Novel Drug Delivery System That Offers Zero-Order/Near Zero-Order Release Profile of Low-Dosage Strength Tablets Containing Highly Soluble Actives
Thomas B. Gold, PhD, was awarded a US patent; the intellectual property centers on formulation development technology that allows for the steady, continuous release of API over a particular duration of time to mitigate variations or spikes in therapeutic benefit.
Patently Disruptive
Derek Hennecke, CEO &President of Xcelience, says Kyle Bass and his hedge fund are challenging pharma patents for the purpose of shorting their stocks and making a fortune and asks is this just industry noise or a true disruption?
SPRAY-DRIED DISPERSIONS - Developing Process Control Strategies for the Manufacture of Spray-Dried Dispersions
Devon DuBose, Dana Settell, Nathan Bennette, and Amber Broadbent, PhD, say drug pipelines increasingly feature new drug candidates that exhibit poor solubility and require well-established enabling technologies to address this critical issue.
MARKET SURVEY - Dosage Forms: It's Time to Listen to Consumers
Thomas Hein, PhD, says in light of their huge success and widespread use, it is easy to assume that tablets and capsules are generally accepted by consumers and the industry.
DNA VACCINE TECHNOLOGY - A Vaccine Breakthrough That Could Change Lives & Enable Vaccine Development Programs
William Hearl, PhD, asks what if there was the potential for a better and safer treatment for allergies, a less-toxic cancer therapy, or a breakthrough treatment to improve the health of a pet or valuable livestock? What if you could employ a new, patented technology that may make these treatments possible?
